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Stroke is one of the leading causes of death worldwide and it brings lots of 
debilitating consequences to those who survive it. There is abundant evidence that 
apoptosis contributes considerably to cell death after ischemic stroke. In the past 
decade, a novel mitochondrial-enriched protein-modulator of apoptosis 1(MOAP-1) 
has been identified to be a Bax-associating protein. In various cell lines, MOAP-1 
promotes caspase-dependent cell death under death stimuli by working as an effector 
for Bax. However, functions of MOAP-1 in live animals have not been characterized 
yet. The present study aimed to investigate the effect of MOAP-1 deletion on brain 
damage in mouse experimental ischemic stroke models.   
The regional and cellular distribution of MOAP-1 in the mouse brain was first 
examined. It was found that MOAP-1was ubiquitously expressed in the mouse brain, 
including the cerebellum, mid-brain, thalamus, hippocampus, striatum, and cortex. 
MOAP-1 immunoreactivity specifically colocalized with immunoreactivity of glial 
fibrillary acidic protein (GFAP) and cluster of differentiation molecule 11B (CD11b 
or OX42), but not with Neuronal Nuclei (NeuN).  GFAP serves as a cell specific 
marker for astrocytes (Brahmachari et al., 2006), OX42 is a maker for monocytes, 
granulocytes, macrophages, and dendritic cells (Domaradzka-Pytel et al., 2000), while 
NeuN is a neuronal specific nuclear protein (Mullen et al., 1992).  
As MOAP-1 was identified to be a Bax effector in vitro, the effect of MOAP-1 
deletion on basal levels of Bax in the mouse brain was examined in MOAP-1-/- 
animals. The successful deletion of MOAP-1 in MOAP-/- animals was confirmed by 
DNA gel and western blot. Interestingly, expression of Bax in the brain after the 
deletion of MOAP-1 was not significantly different from that in wildtype animals. 
Effects of MOAP-1 deficiency to brain damage after cerebral ischemia was studied 
with 3 different experimental ischemic models – transient Middle Cerebral Artery 
Occlusion (tMCAO), permanent Middle Cerebral Artery Occlusion (pMCAO), and 




transient Bilateral Common Carotid Artery Occlusion (tBCCAO), each of which 
brings on different pathophysiological processes and results in diverse infarction 
volumes (Traystman, 2003). However, no significant differences in infarct volumes 
were observed between MOAP-1+/+ and MOAP-1-/- animals after tMCAO or 
pMCAO. Subsequently, expressions of several participating molecules in the 
ischemic cascade were compared between MOAP-1+/+ and MOAP-1-/- animals. 
However, no significant differences were observed. 
In conclusion, the present study demonstrates for the first time that MOAP-1 
protein is widely distributed in the mouse brain, and it is specifically expressed by 
astrocytes, microglia, macrophages, and dendritic cells. However, whether or not its 
deletion causes any changes in the response to a catastrophic event such as stroke 
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CHAPTER 1 INTRODUCTION 
1.1 Stroke 
1.1.1 Definition of stroke 
Stroke occurs when there is a temporary or permanent interruption of blood flow to a 
region of the brain (Paul et al., 2004). Depending on the severity, duration and 
subtype of stroke, it causes symptoms ranging from mild neurological dysfunctions to 
death (Flynn et al., 2008). It is classified into two major types: hemorrhagic stroke 
and ischemic stroke (Doyle et al., 2008). Hemorrhagic stroke happens when a brain 
blood vessel ruptures and blood leaks into surrounding tissue under some pathological 
conditions (Donnan et al., 2008). In ischemic strokes, blood supply to a region of the 
brain is reduced by an occlusion of a cerebral artery (Donnan et al., 2008). This 
obstruction can be caused either by an embolus (a blood clot from elsewhere in the 
body) or a thrombus (a blood clot formed locally) (Dirnagl et al., 1999). Among all 
clinical cases of stroke, ischemic stroke predominates (Woodruff et al., 2011).  
1.1.2 Epidemiology of stroke 
Stroke is a major cause of death worldwide and it causes long-term disability and 
rehabilitation in a large proportion of surviving victims (Woodruff et al., 2011). It is 
the third leading cause of death in the United States ( Lloyd-Jones, D. et al., 2010). 
According to National Institutes of Health’s fact sheet updated in February 2011, 
there is a steady decline of stroke mortality rate in the past several decades in the U. 
S., and it is reduced to about one fourth of what it was about 60 years ago 
(http://report.nih.gov/nihfactsheets/ViewFactSheet.aspx?csid=117).  
In Singapore, stroke is the fourth leading cause of death and it is among the top 10 
reasons for hospitalization (Venketasubramanian and Chen, 2008). Stroke prevalence 





/Pages/projects_gf_Stroke%20Care%20in%20Singapore.aspx). The rate increases 
with age and it is higher in males than in females (Venketasubramanian and Chen, 
2008). Based on a study that is performed more than 20 years ago, the incidence rate 
of stroke in Singapore is about 1.8 per 1000 per year (Venketasubramanian and Chen, 
2008). Since 1990, the crude mortality rate of stroke has declined steadily to about 
40.4/100 000 in 2006 (Venketasubramanian and Chen, 2008). The Singapore 
population is mainly comprised of Chinese, Malaysians and Indians. Interethnic 
studies show that Malay females have the lowest prevalence rate, while they have the 
highest incidence rate and mortality rate for stroke (Heng et al., 2000; 
Venketasubramanian et al., 2005). Ischemic stroke accounts for approximately 3/4 of 
all stroke cases in Singapore, while hemorrhagic stroke accounts for the reminder 
(Venketasubramanian and Chen, 2008).  
Abundant evidence has consistently suggested gender differences in stroke 
(Alkayed et al., 2001). The incidence rate of ischemic stroke is higher in males until 
very late in life (Alkayed et al., 2001), while the outcome is more detrimental in 
females and the mortality rate is higher in females (McCullough et al., 2005). The 
underlying mechanisms that lead to the gender differences remain elusive. Some 
researchers indicated that estrogen protects neurons from ischemic damages (Saleh et 
al., 2009; Zhang et al., 2009). They proposed that the loss of the neuroprotective 
estrogen after menopause explains the significant increase of stroke incidence rate in 
females at late stages of life (Lang and McCullough, 2008). Besides, it is also 
reported that disparities are detected between men and women patients in response to 
different stroke treatments (Lang and McCullough, 2008). Innate differences in 
apoptosis pathways between males and females are suggested to account for these 




1.1.3 Symptoms and diagnosis of ischemic stroke  
Stroke symptoms can develop suddenly. As discussed earlier, the sooner that 
interventions are carried out, the less brain injuries and corresponding neurological 
deficits will be encountered by the patient. Therefore, early recognition of stroke is of 
great importance and can even be lifesaving in some cases.  
FAST is an acronym for the Face Arm Speech test (Nor et al., 2004). This test is 
developed as a widely used tool for the detection of classic stroke symptoms (Nor et 
al., 2004). A person suspected of having stroke is asked to smile to check if sudden 
face drooping has occurred (Harbison et al., 2003). Then the person is required to lift 
both arms up to detect if there is sudden weakness of arms (Harbison et al., 2003). 
Furthermore, the person is asked to repeat a simple sentence to check if he is 
experiencing blurred speech (Harbison et al., 2003). Last but not least, if the above 
symptoms are seen in the person, timely treatment should be carried out. Apart from 
these most notable signs, knowing some other symptoms also helps in the recognition 
of stroke. According to the American National Stroke Association, stroke symptoms 
also include sudden loss of conscious, sudden severe headache of unknown reasons, 
sudden loss of coordination, sudden loss of vision, sudden weakness of legs and so on 
(http://www.stroke.org/site/PageServer?pagename=symp). Besides, a transient 
ischemic attack (TIA) is also a warning sign for stroke (Lovett et al., 2003). A person 
having a TIA shows similar symptoms to those seen in stroke patients while a TIA 
only lasts for less than 24 hours before all the symptoms disappear (Johnston, 2002). 
Patients with TIA can recover completely from it although they are at higher risk of 
stroke (Wolf et al., 1999). Fortunately, this risk can be eliminated if treatments to 
TIAs are carried out in a timely manner (Wolf et al., 1999). 
Once a person is identified with stroke symptoms, immediate medical care is 
needed and a series of tests will be carried out for the diagnosis of stroke. Imaging 




tomography (CT) scans, are performed to get an image of the brain such that the 
location and severability of the stroke can be confirmed (González et al., 1999). Since 
stroke patients are highly likely to have heart diseases and some subtypes of stroke are 
caused by clots from the heart, heart tests, such as electrocardiogram (ECG), are 
performed as well (Goldstein, 1979).  
Some other tests including blood tests and physical examinations also help with the 
evaluation of possible causes of stroke (American Stroke Association).  
1.1.4 Risk factors for ischemic stroke 
There are a number of factors that render some people more prone to stroke than 
others. Some of these risk factors can be modified by medical care or a good lifestyle, 
while others cannot be managed (Donnan et al.).  
Comprehensive studies have revealed that hypertension is a major risk factor for 
stroke (Wolf et al., 1991). High blood pressure weakens blood vessels throughout the 
body, rendering the cerebrovasculature to be more likely to rupture and to develop 
clots (Johansson, 1999). Therefore, it is of great importance to maintain blood 
pressure within the normal range.  
Atrial fibrillation (AF) is also a major risk factor for stroke (Wolf et al., 1991). It is 
characterized by uncoordinated atrial function (Gutierrez and Blanchard, 2011). 
Patients with AF may develop heart failure if they do not undergo treatment for a 
prolonged period of time, leading to insufficient blood supply to the brain (Watson et 
al.). Besides, in patients with AF, atria cannot contract properly such that blood 
cannot be pumped into ventricles completely, resulting in blood stasis and clot 
development, which greatly increase risk for stroke (Gutierrez and Blanchard, 2011).  
Diabetes is another controllable risk factor for stroke (Donnan et al.). People with 
diabetes cannot regulate blood sugar level properly (Snell-Bergeon and Wadwa, 




which increase their risk for stroke (Snell-Bergeon and Wadwa, 2012). In addition, 
patients with diabetes suffer more adverse consequences after a stroke, 
(Snell-Bergeon and Wadwa, 2012).  
Cigarette smoking increases stroke risk as well (Paul et al., 2004). Firstly, toxic 
cigarette constituents can cause endothelial cell damage (Conklin et al., 2002). 
Secondly, smoking leads to production of free radicals that lead to decreased dilatory 
ability of the vasculature (Paul et al., 2004). Moreover, smoking leads to elevated 
levels of thrombin and fibrinogen in the vascular system (Hioki et al., 2001; Magyar 
et al., 2003). Thrombin converts fibrinogen into fibrin, which is a coagulation product 
(Hioki et al., 2001). Therefore, smoking predisposes smokers to an increased risk of 
thrombosis  
Stroke risk also increases with age (Baltan et al., 2008). Aging-related changes in 
the central nervous system (CNS), including vasculature degeneration, protein 
synthesis deterioration, and brain weight loss, render the brain more susceptible to 
ischemic injuries (Chen et al., 2010). Besides, aging diminishes functionality in all 
body systems and thus increases stroke risk. (Chen et al., 2010). Furthermore, women 
have increased stroke risk after menopause due to the loss of estrogen which provides 
neuroprotective effects (McCullough and Hurn, 2003).  
In addition to the factors discussed above, other risk factors for stroke include 
heavy alcohol consumption, family history and previous stroke (Helgason et al., 1994; 
Reynolds K, 2003). Therefore, although the chances of having a stroke cannot be 
eliminated, they can be effectively decreased if particular attention is paid to manage 





1.1.5 Pathophysiology of ischemic injury 
 
Fig. 1.1 Schematic paradigms of the ischemic cascade after ischemic stroke. 
Adopted from Pharmacology Biochemistry and Behavior: Acute ischemic stroke: 
Overview of major experimental rodent models, pathophysiology, and therapy of 
focal cerebral ischemia. (Durukan et al., 2007) 
The human brain has very high metabolic demands (Ishikawa et al., 2004). Although 
it contributes only 2% to the total body weight, it accounts for around 25% of oxygen 




Energy resources are delivered to the brain by blood flow. Compared with other 
organs, the brain is more vulnerable to ischemia because it obtains energy almost 
completely from oxidative phosphorylation with little energy reserve (Hossmann, 
2006a).  
Ample evidence indicates that after ischemia onset, infarct volume grows over a 
period of hours-to-days and infarct progression is resulted from a complex interplay 
of pathways (Doyle et al., 2008). In experimental ischemic stroke, each of these 
pathways has a distinct time frame such that infarct progression is divided into three 
phases: the acute phase, the subacute phase and the delayed phase of injury 
(Hossmann, 2006b). When a cerebral artery is occluded for even a brief period of time, 
oxygen and glucose supply to the corresponding brain territory is severely restricted, 
leading to a rapid decline in glucose-dependent adenosine triphosphate (ATP) 
generation (Woodruff et al., 2011). Cells in the ischemic core will switch to anaerobic 
metabolism from aerobic metabolism and produce less energy. Shortly thereafter, 
tissues in the core of the perfusion deficit will undergo necrotic cell death resulting 
from the loss of energy-dependent processes (Sims and Muyderman, 2010). Tissues 
surrounding the core infarct, where blood supply is reduced to a level that energy 
metabolism can be partially preserved (Astrup et al., 1981) is known as the penumbra. 
If reperfusion is not established in a timely manner, apoptosis will occur and this 
region will gradually progress into infarction (Hakim, 1987). Injuries in this region 
will become irreversible if treatments are not administrated within therapeutic time 
windows (Hakim, 1987). As time goes on, a more delayed phase of injury, which is 
characterized by inflammation, apoptosis and vasogenic edema, further contributes to 
injury progression and it lasts for days to even weeks (Hossmann, 2006a). All the 
deleterious events happen after ischemia onset are collectively referred to as the 
ischemic cascade (Durukan and Tatlisumak, 2007). This cascade includes many major 
mechanisms including the initiation of excitotoxicity and peri-infact depolarization, 




inflammation, and development of reperfusion injury if the brain is reperfused 
(Dirnagl et al., 1999). 
 
Acute phase 
After the commencement of experimental ischemic insult, glucose and oxygen supply 
to a brain territory is interrupted. Within 15 minutes, energy-dependent ion pumps fail 
and ion homeostasis across cell membranes is disturbed in the ischemic region (Rink 
and Khanna, 2011). Subsequently, neurons will depolarize and intracellular calcium 
increases (Martin et al., 1994). The elevated concentration of calcium activates a wide 
array of calcium dependent enzymes, including proteases, lipases and DNases which 
destruct cell structures by degrading cytoskeletal and extracellular matrix proteins, 
destroy cell membranes as well as damage genetic materials in the ischemic core. 
Ultimately cell death ensues because these cellular constitutes cannot be 




The high intracellular Ca
2+
 concentration in the presynaptic neuron triggers the 
release of glutamate (Barnett and Larkman, 2007). Meanwhile, glutamate transporters 
which normally accumulate glutamate into cells fail as they are energy-dependent, 
leading to a further accumulation of glutamate in the extracellular space. Prolonged 
accumulation of glutamate at the synapse initiates excitotoxicity as glutamate 
receptors (especially NMDA receptors) are excessively activated causing Ca
2+
 
overloading in the postsynaptic cells (Olney, 1969). In addition, some cells switch to 
anaerobic metabolism producing lactic acid as a by-product (Doyle et al., 2008). The 




decrease of pH activates pH-sensitive Ca
2+ 
channels, resulting in further calcium 
inflow (Simon, 2006). The aggravated level of cytoplasmic calcium brings 
devastating consequences, including activation of catabolic enzymes and disturbances 
of two calcium storage compartments- mitochondria and endoplasmic reticulum 





postsynaptic cell via the overactivated AMPA channels. Since the level of Na
+ 
influx 
overwhelms the level of K
+ 
efflux, water shifts into the intracellular space passively to 
keep the osmotic equilibrium. This cellular retention of Na
+ 
and water leads to cell 
swellings that are referred to as cytotoxic edema (Rosand and Schwamm, 2001).  
Peri-infarct depolarization 
The subacute phase contributes profoundly to infarct growth (Hossmann, 2006a). 
Cortical spreading depression (CSD) is a wave of cellular depolarization that 
propagates slowly across the cortex (Doyle et al., 2008). Peri-infarct depolarization, 
which is characterized by repetitive depolarizations of cells in the penumbra, 
resembles CSD with the former is quite deleterious while the latter does not cause 
lasting harm (Back et al., 2004; Doyle et al., 2008). During the subacute phase, the 
infarct core expands into the penumbra by peri-infarct depolarization (Hossmann, 
1996). 
As mentioned above, with energy failure, brain cells depolarize due to 
over-stimulation by glutamate and loss of ion homeostasis (Dirnagl et al., 1999). In 
the infarct core, the depolarization is anoxic and irreversible (Lakhan et al., 2009). 
However, in the penumbra region, where the energy supply is greatly insufficient but 
not eliminated, cells undergo intermittent depolarization (Lakhan et al., 2009). Cells 
in this region can repolarize once energy source becomes available again through 
collateral perfusion. However, collateral circulation may not sufficiently meet the 
metabolic demands required (Hossmann, 1996). In addition, glutamate and K
+ 
may 




peri-infarct depolarizations start from the infarct core and develop into the penumbra 
as a spreading depression of electrical activity (Hossmann, 2006a). Consequently, 
infarct volume increases and the number of peri-infarct depolarizations is positively 
associated with final infarct volume (Mies et al., 1993). There is ample evidence that 
peri-infarct depolarization contributes considerably to infarct progression in a variety 
of animal stroke models, however, its relevance in the pathophysiology of human 
stroke has not been well defined yet (Dirnagl et al., 1999). 
Oxidative stress 
Phospholipase A2 (PLA2) is a membrane enzyme that catalyzes the hydrolysis of 
membrane glycerophospholipids to release arachidonic acid (AA) into the 
extracellular space (Burke and Dennis, 2009). AA is one of the most abundant fatty 
acids in the brain and it can reincorporate into the membrane as well as undergo 
oxidative metabolism (Rink and Khanna, 2011). The balance between the two 
pathways is strictly mediated by PLA2 activity (Rink and Khanna, 2011). Stimulation 
of PLA2 depends on phosphorylation and calcium ions (Burke and Dennis, 2009). 
Therefore, the deleterious amount of intracellular Ca
2+
, resulting from ischemia, leads 
to over-activation of PLA2 (Lin et al., 2004). The absence of restriction on PLA2 
activity gives rise to production of reactive oxygen species, such as hydroxyl radicals 
and superoxide (Adibhatla et al., 2003). These free radicals are highly reactive 
molecules that are produced as byproducts of oxidative metabolism (Im et al., 2006). 
They destroy cellular functions by inducing oxidation of lipids, proteins and DNA, 
and they are normally controlled by intrinsic antioxidative systems (Lewen et al., 
2000). After ischemic stroke, the level of free radicals becomes so high that 
endogenous scavenging systems cannot cope with it, leading to membrane damage 
through lipid peroxidation (Allen and Bayraktutan, 2009). Furthermore, nitric oxide 
synthase (NOS)-a calcium-depending enzyme, is highly activated and nitric oxide 
(NO) is generated (Beckman and Koppenol, 1996). Additionally, upon ischemia, 




that promotes superoxide generation (Dirnagl et al., 1999). Subsequently, a powerful 
oxidant-peroxynitrite, formed from NO and superoxide, causes severe tissue injuries 
by damaging a wide range of molecules (Iadecola, 1997).   
In addition, these free radicals also impair the mitochondrial membrane and 
mitochondrial respiration (Dugan and Choi, 1994). Then mitochondrial permeability 
transition pores are formed and cytochrome c is released to activate downstream 




As stroke injuries progress, a strong post-ischemic inflammatory response is evoked 
(Ross et al., 2007). Various brain resident cell populations, such as microglia and 
astrocytes, are activated to release proinflammatory mediators to promote 
post-ischemic inflammation (Gelderblom et al., 2009). After that, neutrophils are 
recruited to brain blood vessels surrounding the ischemic region (Crack and Taylor, 
2005). They adhere to endothelial cell surface through a group of adhesion molecules, 
including intercellular adhesion molecule 1 (ICAM-1) and selectins (Lindsberg et al., 
1996; Zhang et al., 1998). After that, neutrophils transmigrate into the brain 
parenchyma from blood as a result of a breakdown of the blood-brain-barrier (Dirnagl 
et al., 1999). The recruitment of neutrophils contributes to ischemic injuries in two 
ways. Firstly, the accumulation of neutrophil in brain blood vessels obstructs 
restoration of blood flow (Huang et al., 2006). Secondly, once they enter the ischemic 
brain, they induce production of free radicals, such as NO, that worsens ischemic 
outcome (Forster et al., 1999). Afterwards, lymphocytes and monocytes follow to 
infiltrate into the ischemic brain and exert either detrimental or beneficial effects on 
the brain depending on the stage of tissue injury (Iadecola, 1997). The initial 




neuroprotective mechanisms to promote recovery (Bruce et al., 1996; Doyle et al., 
2008).   
After ischemia, transcription factors, such as hypoxia inducible factor 1 (Hif 1) and 
interferon regulatory factor 1 (IRF1), are up-regulated by free radicals and calcium 
ions to induce expression of proinflammatory genes (Dirnagl et al., 1999). Cytokines, 
such as interleukin 1 beta (IL-1β) and tumor necrosis factor α (TNF-α), and 
chemokines are produced and released by injured brain cells (Rothwell and Hopkins, 
1995). These molecules exacerbate brain injuries because administration of their 
receptor antagonists or their neutralizing antibodies attenuates brain injuries and 



















Fig.1.2 Schematic paradigms of extrinsic and intrinsic apoptotic pathways. 
Adopted from Nature Reviews Cancer: Targeting death and decoy receptors of the 
tumor-necrosis factor superfamily. (Ashkenazi, 2002) 
During ischemic brain injury, both necrosis and apoptosis take place (Ankarcrona et 
al., 1995). These 2 distinct classes of cell death differ greatly in their morphological 
and biochemical features, and physiological impact (Ankarcrona et al., 1995). 




detrimental consequences (Bonfoco et al., 1995). Apoptosis, which is also known as 
programmed cell death, is a highly regulated and energy-dependent death process 
(Kerr et al., 1972). It helps the body to eliminate unwanted or dysfunctional cells, and 
it can be either beneficial or devastating under different circumstances (Thompson, 
1995). It is fundamental for multiple physiological processes, such as immune cell 
deletion and the killing of certain pathogens (Love, 2003). It can also be readily 
activated in some kinds of brain injuries and contributes to tissue damage (Rothwell 
and Hopkins, 1995). Furthermore, apoptosis is also involved in the development of 
the nervous system (Ekshyyan and Aw, 2004).  
Many studies have demonstrated that proteins of the Bcl-2 family are key 
regulators of cell death and survival (Adams and Cory, 1998). They are grouped into 
subfamilies of prosurvival and proapoptotic molecules (Martin and Elkon, 2004). For 
example, Bax and Bak promote cell death while Bcl-2 and Bcl-Xl exert opposing 
effects (Martin and Elkon, 2004). The fate of cells are balanced on the opposing 
forces between these two groups of molecules (Reed, 2002).  
It is well-established that apoptosis depends on the action of cysteine-requiring 
aspartate-directed proteases (caspases) in mammals (Love, 2003). It can be triggered 
in a cell either through the extrinsic pathway or the intrinsic pathway in mammalian 
cells (Love, 2003). The extrinsic pathway is initiated by binding of death ligands to 
the transmembrane death receptors, such as the Fas receptors (Ashkenazi, 2002). Then 
the target cell undergoes apoptosis through subsequent activation of caspase-8 and 
caspase-3 (Namura et al., 1998). In contrast, the intrinsic pathway is triggered by 
cellular stress, such as DNA damage (Ashkenazi, 2002). Upon receiving the stress 
signal, Bax and Bak are activated and they translocate to the outer membrane of 
mitochondria to facilitate mitochondrial permeability transition (MPT) by the opening 
of MPT pores (Eskes et al., 2000). Following its membrane insertion, Bax binds to the 
permeability transition pore complex (PTPC), a channel that regulates the 




with adenine nucleotide translocator (ANT), which is a constitutive mitochondrial 
protein, to open MPT pores (Marzo et al., 1998). Consequently, mitochondrial outer 
membrane ruptures due to mitochondria swelling and apoptogenic contents, such as 
cytochrome c, are passively released from mitochondria (Eskes et al., 2000). 
Downstream factors are then activated and degradation of the cell will ensue (Eskes et 
al., 2000). The two apoptotic pathways are not independent from each other because 
extrinsic death stimuli can also assist in the activation of the intrinsic death pathway. 
After stimulation of the extrinsic pathway, active caspase-8 cleaves BID, another 
proapoptotic protein of the Bcl-2 family, into tBID, which activates Bax and Bak to 
promote the intrinsic pathway (Doyle et al., 2008).  
In is reported in the past decade that death receptor-induced Bax conformational 
change and apoptosis requires another protein- Ras association domain-containing 
protein 1A (RASSF1A) (Ghazaleh et al., 2010a). RASSF1A is a cytoskeletal protein 
and it is a member of the RASSF family of proteins (Foley et al., 2008). It is 
traditionally known as a tumour suppressor and its down-regulation can be detected in 
various human cancers (Dammann et al., 2005; van der Weyden and Adams, 2007). 
Subsequently it is shown to be involved in other functions, such as cell cycle arrest, 
genomic stability modulation and apoptosis (Baksh et al., 2005; Foley et al., 2008; 
Song et al., 2005; Song et al., 2004). 
In the past, little attention has been given to the research of delayed damage of 
ischemic stroke. A large body of evidence has shown that focal ischemic damages 
evolve at a slower pace and lasts for a longer period of time than expected previously 
(Dirnagl et al., 1999). Shortly after a focal ischemic onset, the ischemic tissue, which 
is totally depleted of blood supply, undergoes death (Sims and Muyderman, 2010). 
However, ischemic damages do not stop here and a cascade of detrimental events 
takes place at the penumbra-tissues surrounding the core ischemic area. Neurons in 
this region have reduced but not eliminated energy supply such that they will survive 




deficits over time (Dereski et al., 1993). Therefore, much attention has been paid to 
the penumbra in the search for potential treatments for stroke.  
Upon focal ischemia, necrosis predominates in the ischemic core, where injuries 
are acute, while apoptosis prevails in the penumbra, where injuries are milder (Doyle 
et al., 2008). Since mitochondria store calcium ions transiently under normal 
conditions, when the cytosolic level of Ca
2+
 is too high, mitochondria will be 
disturbed (Hossmann, 2006a). Besides, free radicals attack the inner membrane of 
mitochondria to make it more permeable (Hossmann, 2006a). As a result, ion 
gradients across the mitochondrial membrane are lost, causing failure of 
mitochondrial respiration and swelling of mitochondria (Astrup et al., 1981). 
Consequently, apoptogenic molecules, such as cytochrome c, are released from 
mitochondria into cytosol and downstream effectors of the intrinsic apoptotic pathway 
are activated.  
Furthermore, as mentioned earlier, lots of cytokines, such as TNF-α, are produced 
in the post-ischemic inflammation process (Sugawara et al., 2004). TNF-α is a death 
ligand that activates cell surface death receptors. Then the extrinsic apoptotic pathway 
is initiated.  
Additionally, the pathologically high level of intracellular Ca
2+
 activates a wide 
array of enzymes, including proteases, lipases and DNases (Doyle et al., 2008) These 
enzymes lead to activation of Bim, Bax, Bad, and Bid, all of which are proapoptotic 
proteins that promote cytochrome c release. When the cytoskeleton is disassociated by 
proteolytic proteins, Bim is released and then it translocates to the outer membrane of 
mitochondria (Doyle et al., 2008). Furthermore, disruption of DNA by DNases 
activates p53, which induces expression of Bax (Doyle et al., 2008). Bad is activated 
in a calcium-dependent manner (Doyle et al., 2008). Moreover, Bid, which links the 
extrinsic and the intrinsic pathways, is not only activated by caspase-8 after death 




translocation to mitochondria (Doyle et al., 2008)  
On the whole, after ischemia, apoptosis can be induced by an interplay of damaging 
events, including excessive stimulation by glutamate, calcium overload, loss of ionic 
gradients, production of free radicals, death receptor ligation, and degradation of 
proteins (Doyle et al., 2008). Brain injuries become irreversible after 3 h of cerebral 
artery occlusion, therefore, apoptotic neuronal death is more extensive after transient 
than permanent focal brain ischemia (Love, 2003). Since apoptosis is an 
energy-dependent process, if blood supply to the brain is resumed shortly after stroke, 
cell deaths in the penumbra can be significantly reduced and brain functions can be 
restored accordingly (Schaller and Graf, 2004).  
Vasogenic edema 
As ischemic injuries evolve, a large amount of free radicals are produced. These 
radicals work in the vicinity of blood vessels and activate matrix metalloproteases, 
such as MMP9, to disrupt capillary endothelial cell structures (Doyle et al., 2008). 
Then blood brain barrier breaks down 4-6 h after ischemic onset (Hossmann, 2006a). 
Moreover, oxidative stress initiates recruitment of neutrophils as well as leukocytes, 
which further increase vascular permeability (Doyle et al., 2008). Consequently, 
plasma fluid together with macromolecules and serum proteins enter the extracellular 
space of the brain, resulting in vasogenic edema. Vasogenic edema increases 
intracranial pressure, leads to distortion of brain tissue, affects the perfusion of the 
penumbra, and irreversibly contributes to progression of brain injuries (Rosand and 
Schwamm, 2001). Cerebral herniation may result when the increase in brain volume 
is too pronounced (Hossmann, 2006a).  
1.1.6 Therapeutic interventions of ischemic stroke 
Current available anti-ischemic approaches mainly aim at restoration of blood flow 




carried out on thrombolytics and mechanical embolectomy, both of which are for the 
purpose of recanalization (Smith et al., 2005). Compared with neuroprotection, 
thrombolytic treatments are associated with intracerebral hemorrhagic risk (1995b).  
The only FDA-approved drug targeting at acute ischemic stroke is recombinant 
tissue-type plasminogen activator (rtPA), which should be given intravenously within 
3 h of stroke onset (Doyle et al., 2008). tPA is a protein that is found in the 
intravascular space (Haile et al., 2011). It catalyzes the conversion of plasminogen to 
plasmin, which is the main enzyme for clot breakdown (Haile et al., 2011). However, 
only 1–8.5% of hospitalized patients receive treatment with rt-PA due to lack of 
public awareness about early stroke symptoms and the need for a CT scan before 
administration of rtPA to exclude intracranial hemorrhage (Milan et al., 2006). 
Besides, it is only found to be highly effective within a small group of patients 
(1995a). In the NINDS study, only one from seven treated patients is prevented from 
death or disability when systematic administration of rtPA is given within the time 
window (1995a). In the MERCI trail, patients that cannot benefit from rtPA treatment 
were subjected to an alternate approach-mechanical embolectomy (Smith et al., 2005). 
In this new approach, a mechanical embolectomy device is used to disrupt vessel 
occlusion and it is demonstrated that this novel intervention can promote blood 
restoration within 8 h of stroke onset, especially in rtPA ineligible patients (Smith et 
al., 2005). Some other alternative therapeutic approaches involve sonolysis and 
thrombolysis. However, a phase II trial, in which patients were subjected to 
transcranial ultrasound, failed due to an increased rate of cerebral hemorrhage 
(Daffertshofer et al., 2005). Another technical advance of transcranial ultrasound is to 
enhance thrombolysis with the help of targeted gaseous or fluid microbubbles (Sacco 
et al., 2007). The utility of this approach is still under investigation in the 
Interventional Management of Stroke study III trial (Sacco et al., 2007). 
Desmoteplase is another plasminogen activator from the vampire bat (Durukan and 




Desmoteplase in Acute Ischemic Stroke Trial (DIAS) and Dose Escalation of 
Desmoteplase for Acute Ischemic Stroke Trial (DEDAS)  and satisfactory results 
were obtained (Furlan et al., 1996; Hacke et al., 2005). Currently many ongoing trials 
are targeting at combinational therapies, in the hope of finding safe and well-tolerated 
stroke treatments with extended therapeutic time windows. 
After experimental ischemic onset, neuroprotection cannot be achieved in the 
infarct core as tissue in this region dies quickly due to the dramatically reduced 
energy level. However, in the penumbra, where tissues do not die as rapidly as in the 
core infarct, administration of neuroprotective treatments can interfere with those 
injurious processes and delay injury progression until the restoration of blood supply. 
Since each step of the ischemic cascade can serve as a genuine target for treatment, 
multiple neuroprotective interventions targeting at different pathways and molecules 
have been investigated, such as glutamate receptor antagonists, inhibitors of 
mitochondrial permeability pore and calcium channel blockers. Besides, abundant 
evidence has revealed that reperfusion brings on secondary injuries rather than cease 
injury progression (Durukan and Tatlisumak, 2007). Neuroprotection can also 
mitigate these secondary injuries by relieving excitotoxicity, post-ischemic 
inflammation, apoptosis and free radical damage. Examples of these potential 
neuroprotective substances include anti-inflammatory agents, free radical scavengers, 
NO synthase inhibitors and caspase inhibitors.  
However, despite the abundant positive results that have been obtained using 
experimental ischemic models, most therapeutic interventions that were proven to be 
useful in animal models were found to be disappointing in clinical trials (Durukan and 
Tatlisumak, 2007). One possible reason for the translational failure is that in animal 
modeling reperfusion occurs after removal of mechanical occlusion, whereas this is 
totally different from naturally occurring reperfusion patterns. In experimental 
ischemic models, blood flow restores immediately after occlusion. However, in most 




reperfusion (Hossmann, 2006a).  
1.1.7 Animal modeling of ischemic stroke 
The rat is a widely used laboratory species that shares very high similarity with 
humans in the cerebrovascular anatomy (Macrae, 1992). Experimental rats are raised 
under strictly standardized conditions and they have quite high intra-strain 
homogeneity (Brinker et al., 1999). Both of these two properties are necessary for 
getting reproducible experimental results. In addition, breeding cycles for rats are 
quite short and they are relatively inexpensive to maintain compared to other species. 
Furthermore, the small size makes it rather easy to monitor physiological changes 
during ischemia and brain samples can be easily processed for assessment after 
ischemia (Takizawa et al., 1991). Therefore, the rat is a very appropriate species in 
experimental ischemic studies. Besides, the mouse is also frequently used in animal 
ischemic models because mouse is the most suitable animal species for genetic 
modifications (Traystman, 2003). Transgenic studies have provided valuable 
information about participating molecules in stroke.  
Experimental ischemic models that closely resemble human stroke have been 
developed in mice and rats. Major ischemic mechanisms in these models were shown 
to have clinical relevance such that these models serve as good tools for the study of 
pathogenesis of cerebral ischemic injuries and to test effects of potential interventions 
in the preclinical phase (Durukan and Tatlisumak, 2007). Three of the most 
commonly used animal ischemic models are global ischemia, focal ischemia and 
thromboembolic ischemia.  
Global ischemia causes a reduction of blood supply throughout the brain. 
Incomplete global ischemia is frequently induced by 4-vessel occlusion or 2-vessel 
occlusion. In the 4-vessel occlusion model, only rats are used (Traystman, 2003). The 
vertebral arteries of rats are permanently coagulated while the two common arteries 




experimental design (Alps and Hass, 1987; McBean and Kelly, 1998). In the 2-vessel 
occlusion model, only bilateral occlusion of the common carotid arteries is involved 
(Eklöf and Siesjö, 1972). However, 2-vessel occlusion alone is insufficient to produce 
enough brain injuries in rats (Eklöf and Siesjö, 1973). Therefore, in rat 2-vessel 
occlusion model, hypotension is induced together with the bilateral CCA occlusion, 
whereas it is not necessary in mouse 2-vessel model (McBean and Kelly, 1998).    
Focal experimental stroke models are more relevant to human ischemic strokes 
because they mimic human stroke by inducing ischemia in the MCA territory 
(Durukan and Tatlisumak, 2007). In these models, one middle cerebral artery (MCA) 
is occluded at either the proximal or distal site, either transiently or permanently 
(Howells et al., 2010; Longa et al., 1989). In the transient model, infarct volume is 
positively associated with the duration of occlusion (Durukan and Tatlisumak, 2007). 
60-90 min are required to produce a penumbra (Sicard and Fisher, 2009). When 
occlusion lasts for more than 3 hours, brain injuries become irreversible (Smith, 2004). 
Focal ischemia results in a complex sequence of events that contribute to infarction 
progression. Initial damaging effect can be ameliorated by collateral circulation and 
then injuries evolve with time and infarction expands from the ischemic core to the 
penumbra (Furlan et al., 1996). Since injuries at the affected site demonstrate 
heterogeneity that is similar to human ischemic stroke, focal ischemic models are 
indispensable tools in the study of stroke (Traystman, 2003). In transient focal 
ischemia, a suture is inserted into an external carotid artery (ECA) and advanced until 
it reaches the origin of MCA (Durukan and Tatlisumak, 2007). After the designated 
period of occlusion, the suture is removed and reperfusion occurs. Permanent 
ischemia can be induced either by leaving the suture in the position for 24 hours 
(Howells et al., 2010) or by electrocoagulation of the MCA, the latter requires 
craniotomy (Tamura et al., 1981).  
Thromboembolic stroke models have several distinct advantages. Firstly, this type 




2007). Since most of the human strokes are induced by thromboembolism, this model 
is closely linked to human stroke (Durukan and Tatlisumak, 2007). Moreover, 
thrombolysis occurs in this model such that this process can be evaluated and 
thrombolytic agents can be tested (Choi, 1999; Overgaard et al., 1992).  
Each of the above models brings on different pathophysiological processes and 
results in diverse infarction volumes (Traystman, 2003). Therefore, specific steps of 
the ischemic cascade can be looked into and corresponding therapeutic approaches 
can be examined by utilization of different models and modifications of different 
















1.2 Modulator of apoptosis 1 (MOAP-1) 
1.2.1 MOAP-1 is a proapoptotic protein 
In the past decade, a novel brain-enriched protein- MOAP-1 has been identified (Tan 
et al., 2001). It is reported to be a Bax-associating protein by a yeast-two-hybrid 
screen (Schuller et al., 2005; Tan et al., 2005). It has a molecular weight of 39 kDa 
and it is enriched in the outer membrane of mitochondria (Tan et al., 2005; Tan et al., 
2001). MOAP-1 is constitutively degraded by the ubiquitin proteasome complex such 
that its level is kept low in cells under normal conditions (Fu et al., 2007b). In a 
variety of cell lines, MOAP-1 is found to promote caspase-dependent cell death when 
cells are subjected to various death stimuli (Tan, 2005).  
 
Fig.1.3 Schematic paradigms of the formation of TNF-R1/MOAP-1/RASSF1A to 
release its intramolecular inhibition. Adopted from Apoptosis: 14-3-3 Mediated 
regulation of the tumor suppressor protein, RASSF1A. (Ghazaleh et al., 2010a) 
When the transmembrane death receptors, such as TNF-R1 (tumor necrosis factor 
receptor), are activated by their specific ligands present in the extracellular 




electrostatic interactions (Foley et al., 2008). Then the ubiquitination process of 
MOAP-1 is inhibited and the level of MOAP-1 in cells is rapidly elevated (Fu et al., 
2007a). Meanwhile, a pro-apoptotic protein RASSF1A disassociates from its 
inhibitory protein 14-3-3 (Ghazaleh et al., 2010b). Then the TNF-R1-MOAP-1 
complex is internalized and the intramolecular inhibition on MOAP-1 is relieved by 
interacting with RASSF1A (Law et al., 2012). The TNF-R1/MOAP-1/RASSF1A 
complex induces the conformational change of Bax and facilitates its translocation 
from cytosol to the mitochondrial outer member (Vos et al., 2006). Then Bax 
oligomerizes with Bak and renders the mitochondrial membranes permeable by 
formation of the mitochondrial permeability transition (MPT). Consequently various 
apoptogenic molecules, such as cytochrome c, are released from the mitochondrial 
matrix into the cytosol (Danial and Korsmeyer, 2004). Then downstream caspases, 
mainly caspase-3, are activated to initiate cell death (Danial and Korsmeyer, 2004). 
1.2.2 MOAP-1 is a member of the Paraneoplastic Ma antigens gene family 
Paraneoplastic neurological syndromes (PNS) are immune-mediated diseases that are 
clinically relevant to cancer (Darnell and Posner, 2003b; Mielke, 1970; Voltz, 2002). 
The onconeural antigens are common antigens in cancer and the nervous system 
(Monstad et al., 2009). The onconeural antigens of the cancer cells trigger an 
autoimmune reaction and the resultant onconeural antibodies attack not only the 
neoplastic tissue but also the nervous system causing PNS (Darnell and Posner, 
2003b). PNS can affect any part of the nervous system, including the central nervous 
system, the peripheral nervous system, as well as the neuromuscular junction 
(Honnorat and Antoine, 2007). The neurological damage is progressive and can be 
severe and disabling (Honnorat and Antoine, 2007). However, PNS are rare diseases 
that occur in less than 0.01% of cancer patients (Darnell and Posner, 2003a). Besides, 
development of the neurological symptoms often precedes the detection of cancer, 




All the onconeural antigens identified in human PNS are grouped into the 
Paraneoplastic Ma antigens (PNMA) family. There are 6 members in this family: 
PNMA1, PNMA2, PNMA3, PNMA4 (MOAP-1), and two hypothetic proteins - 
PNMA5 and PNMA6 (Schüller et al., 2005). Expression profiles of these proteins are 
established and they differ greatly from one another. It is reported that all of the first 4 
members are expressed in human adult brain and amino acid sequence homologies 
range from 44% to 54% between them (Schüller et al., 2005). MOAP-1 shows with a 
54% homology with PNMA1 and a 44% homology with both PNMA2 and PNMA3 
(Schüller et al., 2005). 
1.2.3 Expression profile of MOAP-1 
MOAP-1 is found to be expressed in different mammalian species (Schuller et al., 
2005), including human, mouse and rat (Takaji et al., 2009). Compared to rat and 
mouse MOAP-1, human MOAP-1 shares a 77% and 76% homology, respectively. 
(Schuller et al., 2005). Both human and mouse MOAP-1 protein is most abundantly 
expressed in the brain as demonstrated by northern analysis and immunoprecipitation 












1.3 Research rational and objectives 
Hitherto, there are virtually no animal studies on MOAP-1 published in the literature 
and the physiological roles of MOAP-1 in the CNS remains unknown. However, 
MOAP-1 knockout mice are available. Based on the involvement of MOAP-1 in the 
apoptotic pathway, we hypothesize that MOAP-1 deficiency in the knockout mice 
would render them more resistant to tissue damage in the event of ischemic injuries in 

















CHAPTER 2 MATERIALS AND METHODS 
2.1 Animals 
Experimental protocols and animal breeding protocols used in this study were 
approved by the Institutional Animal Care and Use Committee (IACUC) at National 
University of Singapore. Studies were carried out on male MOAP-1 knockout and 
C57BL/6 wildtype mice, weighing 20-25g. All animals were kept in the University 
Animal Holding Unit on a 12 h light/dark cycle and they were allowed free access to 
food and water. MOAP-1 knockout breeding pairs were obtained from Assoc Prof 
Victor Yu. 8-week-old wildtype animals were obtained from the University 
Laboratory Animals Center and maintained until they reach the desirable age.  
2.2 Transient Middle Cerebral Artery Occlusion (tMCAO) 
Anesthesia was induced with a ketamine-xylazine cocktail (100mg/kg and 10mg/kg, 
i.p.), purchased from the University Animal Holding Unit. Temperature of animals 
was maintained at 36.5 °C to 37.5 °C with a heating pad throughout the surgery. 
Middle cerebral artery occlusion was induced as previously described (Bouët et al., 
2007; Longa et al., 1989). After anesthesia, a midline incision was made at the neck 
of the animal. Then the right common carotid artery (CCA) was carefully isolated 
from surrounding tissues under a surgical microscope (Olympus America). The 
external and internal carotid arteries (ECA and ICA) were then exposed from the 
bifurcation of the CCA. After that, the pterygopalatine artery and the distal end of the 
ECA were ligated close to their origins with a 7-0 nylon suture (B. Braun, Melsungen, 
Germany). Then the ECA stump was loosely tied by the same suture and the ICA 
stump and the CCA were occluded by microvascular clips.  A 3-cm 7-0 
monofilament silicon-coated nylon suture (Doccol Coporation, Sharon, MA, USA) 
was then inserted into the lumen of the ECA at the proximal end and advanced into 




confirmed by an effective reduction of cerebral blood flow (CBF) to around 15% of 
the initial value. This reduction was monitored by a laser-Doppler flowmetry (FloLab 
Moor Instruments) probe that was positioned on the right side of the skull (2 mm 
lateral and 1 mm posterior to the bregma). The occlusion lasted for 2 h until the suture 
was withdrawn. The incisions were closed with silk sutures (B. Braun, Melsungen, 
Germany) and the animals were euthanized 22 h later. Sham-operated animals 
underwent the same procedures but without the insertion of the silicon-coated nylon 
suture. 
2.3 Permanent Middle Cerebral Artery Occlusion (pMCAO) 
pMCAO was performed exactly as described for tMCAO above until the suture was 
inserted to occlude the MCA. A laser-Doppler was used to confirm the occlusion as 
seen in tMCAO. Then the loose tie at the ECA stump was tied securely without 
withdrawing the suture. The incisions were closed with silk sutures (B. Braun, 
Melsungen, Germany) and the animals were euthanized after 24 hours. 
Sham-operated animals underwent the same procedures except for insertion of the 
silicon-coated nylon suture. 
2.4 Transient Bilateral Common Carotid Artery Occlusion (tBCCAO) 
Animals were anesthetized with body temperature maintained at 36.5 °C to 37.5 °C as 
described above. Then both the right and the left common carotid arteries were 
carefully isolated from their surrounding tissues under a surgical microscope 
(Olympus America Inc.). Then the CCAs were occluded with microvascular clips for 
30 min. Cerebral blood flow in the right middle cerebral artery territory (2 mm lateral 
and 1 mm posterior to the bregma) was monitored by a Laser-Doppler flowmetry 
probe. A successful occlusion was confirmed by an effective reduction of cerebral 
blood flow (CBF) to around 10% of the initial value. Then incisions were closed with 




animals were euthanized 23.5 h later. Sham-operated animals underwent the same 
procedures without applying the clips. 
2.5 Determination of infarct volume and edema index by TTC staining 
Operated animals were euthanized with carbon dioxide for the assessment of infarct 
volume and edema index. After decapitation, brains were removed and cut into 2 mm 
coronal sections in a cutting block. Then the brain slices were immersed in 0.2% 
2,3,5-triphrnyltetrazolium chloride (TTC, Sigma-Aldrich, St. Louis, MO, USA) 
solution at room temperature for 30 min. Stained brain slices were flipped over and 
the posterior sides of the slices were imaged by a camera. The infarct size and surface 
area of each brain slice were measured with image analysis software (Image J, 
Bethesda, MD, USA). The percentage of brain infarction was calculated as: (the sum 
of the infarct areas of all slices) x 2 mm / (the sum of surface areas of all slices) x 2 
mm. Edema index was calculated as the following: (the sum of ipsilateral hemispheric 
areas of all slices) x 2 mm / (the sum of contralateral hemispheric areas of all slices) x 
2 mm. The percentage of brain infarction was corrected by edema index as: the 
corrected percentage of brain infarction = the percentage of brain infarction / edema 
index. 
2.6 DNA extraction 
Tail snipping was carried out on the 21
st
 day of age of the MOAP-1 KO mice. It was 
then put into tail lysis buffer (50 mM Tris, pH 8.8; 100 mM NaCl; 100 mM EDTA; 
1% SDS) in the presence of proteinase K (Sigma-Aldrich, St. Louis, MO, USA). The 
sample was gently shaked overnight at 55 °C. After tail digestion, saturated NaCl 
solution was added into the sample and it was shaked for another 5 min and then 
centrifuged at 14 000 rpm in a precooled centrifuge (4 °C) for 20 min. Isopropanol 
was added to the supernatant and then centrifuged for 12 min. The resultant DNA 




After standing for at least 10 min, the sample was centrifuged for 7 min, and the 
supernatant was discarded and DNA pellet was dried at room temperature. Dried 
DNA pellet became transparent and was incubated in autoclaved water at 37 °C for 30 
min. DNA concentration was measured by NanoDrop Spectrophotometer (Thermo 
scientific, Wilmington, DE, USA) and then stored at 4 °C ready for use. 
2.7 Gene expression analysis  
DNA samples were adjusted to the same concentration and equal amounts of DNA 
samples from MOAP-1 knockout, MOAP-1 heterozygous as well as wildtype mice 
were subjected to PCR for amplification. The Qiagen HotStarTaq Master Mix Kit 
(Qiagen, Valencia, CA, USA) and primers (Table 2.1, obtained as a gift from Prof 
Victor Yu) were added to the DNA samples and amplified under the following 
conditions: a: 95 °C (for 15 min); b: 95 °C (for 40 sec); c: 58 °C (for 40 sec); d: 72 °C 
(for 2 min), e: 72 °C (for 5 min). Steps b-d were repeated for 40 cycles and after the 
last step, the reaction paused at 4 °C. Absence of MOAP-1 in MOAP-1-deficient 
animals was confirmed using 1% agarose gel in the presence of ethidium bromide. 
The gel was then visualized by GelDoc-It Imaging System and DNA densities were 












Table 2.1   
Primers for PCR reactions 
Protein name Primer sequence Size 
(bp) 
WT MOAP-1  Forward: 5’-ATCCATCCCATCCGCTGACG-3’ 528 
 Reverse: 5’-GACTCTTGCTCGCTTGCAGG-3’ 

















2.8 Tissue preparation for western blot analysis 
After deep anesthesia with carbon dioxide, animals were perfused with 
phosphate-buffered saline (PBS, pH 7.4). Brains were removed and dissected into 
cerebellum, mid-brain, thalamus, hippocampus, striatum and cortex. Each region of 
the brain was homogenized with lysis buffer (Cell Signaling Technology, Danvers, 
MA, USA), which contains complete protease inhibitor cocktail ((Roche Diagnostics, 
Penzberg, Germany). Homogenized samples were centrifuged at 12000 g in a 
precooled centrifuge (4 °C) for 20 min. The supernatant containing the cytosolic 
fraction was used. Protein concentrations were determined with a NanoDrop 
spectrometer (Thermo scientific, Wilmington, DE, USA) with bovine serum albumin 
as standard (Pierce Biotechnology, Rockford, IL, USA) for calibration. All samples 
were adjusted to 30 mg/μl with PBS buffer and then diluted with laemmli buffer 
(Bio-Rad, Hercules, CA, USA) at a 1:1 ratio. 
2.9 Western blot analysis 
Equal amounts of protein (150 mg/well) were separated by a 10% sodium dodecyl 
sulfate-polyacrylamide (SDS/PAGE) gel. Then the gel was transferred onto a 
nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). To prevent unspecific 
binding, the membrane was blocked with 10% nonfat dry milk (Bio-Rad, Hercules, 
CA, USA) in PBST buffer (1 x PBS, 0.1% Tween-20, pH 7.4) at room temperature 
for 1 h. Following that, the membrane was subjected to incubation with primary 
antibodies against MOAP-1 (Sigma-Aldrich, St. Louis, MO, USA), Bax (Abcam, 
Cambridge, MA, USA), NeuN (Cell Signaling Technology, Danvers, MA, USA), 
GFAP (Abcam, Cambridge, MA, USA), HIF-α (Abcam, Cambridge, MA, USA), 
MMP-9 (Abcam, Cambridge, MA, USA), Cytochrome c (Cell Signaling Technology, 
Danvers, MA, USA) or β-actin (Cell Signaling Technology, Danvers, MA, USA) at 4 




3) and then incubated with corresponding horseradish peroxidase-conjugated (HRP) 
secondary antibodies (Santa Cruz Biotechnology, Dallas, TX, USA) for 1 h at room 
temperature. Afterwards, the membrane was washed again with PBST (10min x 3). 
Visualization was carried out using Luminate Forte/Crescendo Western HRP 
Substrates (Millipore Corporation, Billerica, MA, USA) and protein bands were 
analyzed and quantified by a transilluminator (UVItec Limited, Cambridge, UK). 
Protein levels were normalized to β-actin (Cell Signaling Technology, Danvers, MA, 
USA). 
2.10 Tissue preparation for immunofluorescence staining 
Shortly after animals were euthanized with carbon dioxide, they were perfused 
thoroughly with saline (0.9% NaCl solution) and 4% paraformaldehyde solution in 
succession. After perfusion, brains were removed and immersed in 4% 
paraformaldehyde solution overnight at 4 °C. Then brains were dehydrated in 20% 
sucrose solution at 4 °C overnight before proceeding to dehydration with 30% sucrose 
solution for 1 day. After dehydration, brains were coated with Tissue-Tek Optimal 
Cutting Temperature (OCT) compound (Sakura Finetek, Torrance, CA, USA) and 
placed in the cryostat (Leica Biosystems, Wetzlar, Germany) chamber. Coronal 
sections (20 µm) were cut and mounted onto glass slides (Matsunami Glass, Osaka, 
Japan) and stored at -20 °C for use. 
2.11 Immunofluoresence staining  
Slide-mounted brain sections were dried at room temperature and washed with 
PBS-Tx (0.01M PBS with 0.1% Triton-x) 3 times. Then sections were blocked with 
5% goat serum for 1 h at room temperature to prevent unspecific binding. After that, 
slides containing consecutive brain sections were incubated with anti-MOAP-1 
antibody (1: 200, Sigma-Aldrich, St. Louis, MO, USA) together with one of 




Cambridge, MA, USA) , anti-OX42 (Abcam, Cambridge, MA, USA), and anti-BAX 
(Abcam, Cambridge, MA, USA) antibodies overnight at 4 °C. On the next day, 
sections were washed with 0.01M PBS solution 3 times and incubated with secondary 
antibodies (1: 200, Merck Millipore, Billerica, MA, USA)) for 1 h at room 
temperature and then washed in PBS 3 more times and counterstained with DAPI for 
2 min. Sections were mounted with Dako Fluorescent mounting medium (Dako, 
Glostrup, Denmark) and analyzed using a confocal laser microscope (Nikon Digital 
Sight DS-R). 
2.12 Data analysis  
Statistical analysis was performed using SPSS. All data are presented as mean ± SEM. 
Comparison of means of multiple groups was done by one-way ANOVA with Tukey 
post hoc test. Comparison of means between two groups was done by independent 














CHAPTER 3 REGIONAL AND CELLULAR DICTRIBUTION OF MOAP-1 IN 
THE BRAIN 
3.1 Introduction 
In the past decade, MOAP-1 has been identified to be a mitochondria-enriched protein 
in various mammalian cell lines (Tan, 2005). Moreover, since MOAP-1 is a member 
of the PNMA family of proteins (Schuller et al., 2005), its distribution was 
investigated briefly in a study that examined the expression pattern of PNMA5 
mRNA in the brain (Takaji et al., 2009). Takaji and colleagues examined all the 
expression patterns of PNMA1, PNMA2, PNMA3, PNMA4 (MOAP-1) and PNMA5 
mRNAs in the African green monkeys and mice by northern blot hybridization and in 
situ hybridization (ISH). MOAP-1 mRNA was detected in the neocortex, cerebellum 
and spinal cord of the African green monkeys and it was abundantly expressed in the 
cerebrum, cerebellum and testis of mice by northern blot hybridization (Takaji et al., 
2009). The ISH results demonstrated that MOAP-1 mRNA was also expressed in the 
striatum and thalamus in the mouse brain (Takaji et al., 2009). However, apart from 
this study, detailed distribution profiles and physiological functions of MOAP-1 
protein in animals remain unknown.  
As MOAP-1 mRNA demonstrates a relatively high expression in the mouse brain, 
we sought to examine the distribution of MOAP-1 protein in the mouse brain. Besides, 
the availability of MOAP-1-/- animals renders it possible for us to explore possible 
functions of MOAP-1 protein. In this study, it is demonstrated for the first time the 
regional and cellular distribution of the MOAP-1 protein in the mouse brain. In 
addition, Bax expression was also investigated as MOAP-1 was reported to be a 





3.2.1 Expression profiles of MOAP-1 and Bax proteins in the brain of 
MOAP-1+/+ mice 
Basal levels of MOAP-1 and Bax proteins were checked in the brain of a wildtype 
C57BL/6 mouse. As shown in Fig 3.1, MOAP-1 had a heterogeneous expression 
pattern throughout the brain. It was strongly expressed in the cortex and weakly 
expressed in the striatum. The same expression pattern was not observed in Bax 
protein. Bax showed relatively higher expression in the cerebellum, mid-brain, 










































































































































Fig. 3.1 Regional distribution of MOAP-1 and Bax proteins in the brain of a 
MOAP-1 +/+ mouse. Proteins were extracted and subjected to western blot analysis 
using the anti-MOAP-1 and anti-Bax antibodies. Data are presented as the ratio to the 






Immunofluorescence staining revealed that MOAP-1 was ubiquitously expressed in 
the mouse brain, consistent with Western blot results shown in Fig. 3.1. Fig 3.2 shows, 
MOAP-1 immunoreactivity in the hippocampus (A) and cortex (B).  
 
Fig. 3.2 Localization of MOAP-1 in the hippocampus and cortex of MOAP-1 +/+ 
mice. (A) MOAP-1 immunoreactivity (green) was found in the hippocampus. (B) 
MOAP-1 immunoreactivity (green) was found in the cortex. Data for other brain 
regions were not shown. 
 
3.2.2 Cellular distribution of MOAP-1 in the brain 
To identify cell types that express MOAP-1 in the brain, double immunofluorescence 
staining was performed. Brain sections were incubated with antibodies targeting at 
MOAP-1 and NeuN, or GFAP, or OX42, respectively. As shown in Fig. 3.3, 
MOAP-1 immunoreactivity colocalized with immunoreactivity GFAP and CD11b/c 
(OX42), but not with NeuN, indicating that MOAP-1 was expressed in astrocytes and 










Fig. 3.3 Cellular localization of MOAP-1 in the hippocampus of MOAP-1 +/+ 
mice. MOAP-1 immunoreactivity colocalized with GFAP, OX42, but not with NeuN. 
(A) MOAP-1 immunoreactivity (green) colacolizes with a marker for astrocytes (red). 
(B) MOAP-1 immunoreactivity (green) is colacalizes with a marker for monocytes, 
granulocytes, macrophages, dendritic cells (red). (C) MOAP-1 immunoreactivity 
(green) does not colacolize with a marker for neuronal cells (red). 
3.2.3 Confirmation of MOAP-1 deletion in MOAP-1-/- mice 
To check if MOAP-1 deletion was successful, both tail DNA samples and brain 
lysates (cortex) from animals were subjected to analysis to detect the presence of 
MOAP-1 gene and its translational product. After being amplified by PCR, DNA 
samples from MOAP-1+/+, MOAP-1-/- as well as MOAP-1+/- mice were separated 
by agrose gel and two bands were identified. They were of similar size to 
MOAP-1+/+ and MOAP-1-/- primers, which were 528 bp and 799 bp, indicating 
successful deletion of MOAP-1 gene (Fig3.4 A). To further confirm that there is no 
functional MOAP-1 protein in MOAP-1-/- mice, western blot was carried out on brain 
lysates of MOAP-1+/+ and MOAP-1-/- mice and the result was consistent with those 






Fig. 3.4 Confirmation of MOAP-1 deletion in MOAP-1-/- mice. (A) Tail DNA 
samples from MOAP-1+/+, MOAP-1-/- and MOAP-1+/- mice were amplified by 
PCR using corresponding MOAP-1 primers and then subjected to agrose gel. Two 
bands between 1000 and 500 bp were observed. (B) Brain lysates (cortex) of 
MOAP-1+/+ and MOAP-1-/- mice were subjected to western blot analysis using the 
anti-MOAP-1 antibody. WT: MOAP-1+/+; KO: MOAP-1-/-, N = 3. 
 
3.2.4 Comparison of basal levels of Bax protein in the brain of MOAP-1+/+ and 
MOAP-1-/- mice 
Since MOAP-1 was identified to be a Bax-effector in the apoptotic pathway (Tan, 
2005), we would like to check if the deletion of MOAP-1 affects the basal level of 
Bax protein in the brain. As shown in Fig. 3.5, after the deletion of MOAP-1, 




animals.   
 



























Fig. 3.5 Basal expression level of Bax in MOAP-1 +/+ and MOAP-1-/- mice. Brain 
lysates were extracted and subjected to western blot analysis using the anti-Bax 












3.3 Discussion   
Hitherto, no detailed information about the distribution of MOAP-1 protein in the 
brain is available in the literature. In our study, brains from wildtype C57BL/6 mice 
were dissected into different regions and subjected to western blot analysis. The 
results obtained demonstrated that MOAP-1 was a ubiquitously expressed protein in 
the mouse brain, and this observation was further confirmed by immunofluorescence 
staining. This is consistent with previous findings that MOAP-1 mRNA is strongly 
expressed in mouse brain (Takaji et al., 2009). The abundant expression of MOAP-1 
protein in the brain suggests that it may exert some important functions for the normal 
functioning of the brain.  
It would be greatly helpful to identify cell types that express MOAP-1 before 
moving on to investigate its possible functions. From our observations, we can 
conclude that MOAP-1 is expressed in astrocytes and other glial cells rather than 
neurons. Collectively, glial cells outnumber neurons greatly (Sofroniew and Vinters, 
2010). Besides, glial cells exert many essential functions in the healthy CNS and they 
also demonstrate specialized functions in response to CNS injuries. Therefore, the 
expression of MOAP-1 in these cells suggests that it may play important roles in 
supporting brain functions.  
The successful creation of MOAP-1-/- animals serves as a helpful tool for the study 
of MOAP-1 functions. If any notable changes were detected in MOAP-1 deficient 
animals compared with wildtype controls, these changes could be directly attributed 
to the deletion of MOAP-1. However, all the MOAP-1-/- animals were viable and 
demonstrated normal phenotypes, ensuring that MOAP-1 was not a vital protein in the 
normal development of mice such that its deficiency did not cause lethal 
consequences. Despite no observable defects were observed in MOAP-1-/- mice, 
some underlying physical mechanisms might be different and they might produce 




  It has been reported that MOAP-1 works as a mitochondrial effector for Bax in the 
caspase-dependent apoptotic pathway in mammalian cell lines (Tan, 2005), therefore, 
it is interesting to investigate if the deletion of MOAP-1 affects the expression level of 
Bax in the mouse brain. However, disappointing results were observed. Several 
possible reasons may account for this observation. Firstly, MOAP-1 may exert 
different functions in living animals rather than working as a Bax effector. Secondly, 
if MOAP-1 promotes Bax activation in vivo, it may not be the only effector for Bax, 
some unknown mechanisms might exist that lead to activation of Bax under death 















CHAPTER 4 EFFECTS OF MOAP-1 DEFICIENCY IN THE 
EXPERIMENTAL PMCAO MODEL 
4.1 Introduction 
As a majority of clinical ischemic strokes involve the MCA (Chiang et al., 2011), 
rodent ischemic models focusing on this artery provide the experimental backbone for 
the study of stroke. Among all the models, the intraluminal suture model of middle 
cerebral artery occlusion is the most widely used technique at present. This model can 
induce either permanent or transient focal ischemia depending on the duration of 
occlusion. MCAO produces ischemic tissue death primarily in the striatum and cortex 
(Carmichael, 2005). When ischemia is severe, infarct volumes become substantial 
such that they progress into other brain structures, such as the hippocampus and 
thalamus (Maeda et al., 1999).  
Abundant studies have shown that upregulation of matrix metalloproteinase 9 
(MMP9), which is a proteolytic enzyme, is implicated in the pathogenesis of stroke 
(Romanic et al., 1998). Furthermore, as mentioned earlier, HIF-1α is frequently 
observed to be increased after MCAO (Chang et al., 2009). In addition, astrocyte 
hypertrophy and proliferation is also a common pathological process following 
MCAO (Wang et al., 2008). Moreover, as previously discussed, apoptosis contributes 
to ischemic injuries considerably; therefore, expression of cytochrome c is also 
increased from mitochondria-dependent apoptotic pathways. Collectively, these 
molecules play important roles in the ischemic cascade. 
In order to investigate if MOAP-1 deficiency decreases susceptibility to brain 
damage after cerebral ischemia, we induced MCAO in both MOAP-1+/+ and 
MOAP-1-/- animals. Infarct volumes, MMP-9, HIF-1a and cytochrome c were 





4.2.1 MOAP-1 deficiency does not decrease susceptibility to brain damage 
after permanent focal ischemia  
Twenty four hours after permanent focal ischemia, MOAP-1+/+ and MOAP-1-/- mice 
were euthanized and TTC staining was performed on their brain slices. Fig 4.1(A) 
shows representative stating results for these two groups of mice and Fig 4.1(B) 
shows quantification of infarct volumes. Infarct volumes did not demonstrate a 
significant difference between the two groups, indicating MOAP-1 deficiency did not 





















Fig 4.1. Effect of MOAP-1 deletion on infarct volume after pMCAO. The effect is 
evaluated by TTC staining. (A) Representative TTC-stained sections of brain. 
Infarcted tissues appeared white in color as they are not stained by TTC. (B) 
Quantification of infarct volume in the brain sections. Data are mean ± SEM, N = 7. 
 
4.2.2 Effects of MOAP-1 deficiency and permanent focal ischemia on 
expressions of various molecules of the ischemic cascade in the hippocampus 




significantly increased expression of MMP9 in the hippocampus compared with 
sham animals (Fig. 4.2). However, the deletion of MOAP-1 did not induce any 
changes in MMP9 expression in the hippocampus (Fig. 4.2).  
 
 
Fig. 4.2 Expression of MMP9 protein in the hippocampus before and after 
pMCAO in MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and subjected 
to western blot analysis using the anti-MMP9 antibody. Data are presented as mean ± 
SEM, N = 3, *P < 0.05. 
 
4.2.3 Effects of MOAP-1 deficiency and permanent focal ischemia on 
expressions of various molecules of the ischemic cascade in the striatum 




differences in expressions of cytochrome c and HIF-α in the striatum (Fig. 4.3 and 
4.4). In the terms of GFAP, permanent focal ischemia induced significantly increased 
GFAP expression in the striatum in MOAP-1+/+ mice, however, no such significant 
changes were observed in MOAP-1-/- mice. Besides, deletion of MOAP-1 did not 
affect GFAP expression in both sham and surgery-operated animals (Fig. 4.4). In 
contrast, MMP9 did not change significantly in MOAP-1+/+ animals following 
permanent focal ischemia but it was significantly augmented in MOAP-1-/- animals. 






































Fig. 4.3 Expression of Cytochrome c protein in the striatum before and after 
pMCAO in MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and subjected 
to western blot analysis using the anti-Cytochrome c antibody. Data are presented as 




































Fig. 4.4 Expression of HIF-α and GFAP proteins in the striatum before and after 
pMCAO in MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and subjected 
to western blot analysis using the anti-HIF-α and anti-GFAP antibodies. Data are 







Fig. 4.5 Expression of MMP9 protein in the striatum before and after pMCAO in 
MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and subjected to western 
blot analysis using the anti-MMP9 antibody. Data are presented as mean ± SEM, N = 








4.2.4 Effects of MOAP-1 deficiency and permanent focal ischemia on 
expressions of various molecules of the ischemic cascade in the cortex 
Neither permanent focal ischemia nor MOAP-1 deletion brought about any significant 
differences in expression of cytochrome c in the cortex (Fig. 4.6). HIF-1α, did not 
change significantly in MOAP-1+/+ animals following permanent focal ischemia but 
it was significantly augmented in the cortex of MOAP-1-/- animals. Again, MOAP-1 
deletion did not alter HIF-α expression in both sham and surgery-operated animals 
(Fig. 4.7). In the terms of GFAP and NEUN, permanent focal ischemia induced 
significantly increased GFAP and NEUN expressions in the cortex in both 
MOAP-1+/+ and MOAP-1-/- mice. Besides, deletion of MOAP-1 did not affect 
GFAP and NEUN expressions in both sham and surgery-operated animals (Fig. 4.7 
and 4.9). For MMP9, permanent focal ischemia led to significantly increased MMP9 
expression in the cortex of MOAP-1+/+ mice, while the increment was not so 
considerable in MOAP-1-/- animals. Furthermore, MOAP-1 deletion did not exert any 
















































Fig. 4.6 Expression of Cytochrome c protein in the cortex before and after 
pMCAO in MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and subjected 
to western blot analysis using the anti-Cytochrome c antibody. Data are presented as 



















pMCAO in MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and subjected 
to western blot analysis using the anti-HIF-α and anti-GFAP antibodies. Data are 








Fig. 4.8 Expression of MMP9 protein in the cortex before and after pMCAO in 
MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and subjected to western 
blot analysis using the anti-MMP9 antibody. Data are presented as mean ± SEM, N = 










Fig. 4.9 Expression of NeuN protein in the cortex before and after pMCAO in 
MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and subjected to western 
blot analysis using the anti-NeuN antibody. Data are presented as mean ± SEM, N = 3, 












MOAP-1’s proapoptotic function in mammalian cell lines and its relatively high 
expression in the mouse brain led to the possibility that MOAP-1 might exert a 
proapoptotic function in the mouse brain and its deletion could decrease brain 
susceptibility to ischemic injuries. However, after pMCAO, brain infarct sizes were 
not significantly different between MOAP-1+/+ and MOAP-1-/- mice, suggesting that 
the deletion of MOAP-1 did not improve ischemia outcomes. Again, there are several 
possible reasons for this disappointing result. Firstly, MOAP-1 may work as a Bax 
effector in the mouse brain. However, under pathological conditions, although 
MOAP-1 deletion attenuates Bax activation through abolishment of this mechanism, 
some other unknown proapoptotic mechanisms might exist to cancel out this effect. 
Secondly, it is also possible that MOAP-1 may exert opposite effects at different 
ischemic stages or through different pathways such that its proapoptotic effects are 
counteracted by its neuroprotective effects. Last but not least, it is also possible that 
MOAP-1 is not involved in cell death pathways in vivo; therefore its deletion does not 
affect infarct sizes after ischemic injuries.  
To investigate if MOAP-1 deletion changes expressions of several known members 
of the ischemic cascade, brain lysates were subjected to western blot. In the 
hippocampus, significant increase of MMP9 level was induced by pMCAO in both 
MOAP-1+/+ and MOAP-1-/- mice. However, MOAP-1 deficiency did not cause such 
difference between MOAP-1+/+ and MOAP-1-/- mice. As mentioned earlier, MMP9 
level increases after ischemic onset and it contributes to ischemic injuries through 
degradation of cell structures (Romanic et al., 1998). Therefore, our result shows that 
deletion of MOAP-1 did not affect the upregulaiton of MMP9 in the hippocampus 
after ischemia. 




mice but the increment was not significant in MOAP-1-/- mice. Since astrocyte 
proliferation is a well-established phenomenon after ischemic injuries (Wang et al., 
2008), our results demonstrated that MOAP-1 deletion sequestered GFAP 
upregulation in response to ischemic injuriets through some unknown mechanisms. 
MMP9 expression was also increased in both MOAP-1+/+ and MOAP-1-/- animals 
after permanent focal ischemia, however, the augmentation was only significant in 
MOAP-1 deficient animals, suggesting MOAP-1 deletion led to a more pronounced 
MMP9 expression after ischemia. It has been well-established that apoptosis plays a 
vital role in the progression of ischemic injuries and consequently large amount of 
cytochrome c is released into the cytoplasm. Surprisingly, significant increase of 
cytochrome c expression was not observed in both MOAP-1+/+ and MOAP-1-/- 
animals after ischemia. A possible explanation might be the majority of the striatum 
tissue underwent death such that although the remaining tissue secreted increased 
amount of proapoptogenic cytochrome c, the total amount of proteins did not increase.  
In the cortex, deletion of MOAP-1 did not suppress astrocyte proliferation as seen 
in the striatum. In addition, MMP9 expression was significantly increased and NeuN 
expression was significantly reduced after ischemia in both MOAP-1+/+ and 
MOAP-1-/- mice, and these results were in agreement with the fact that MMP9 
increases and neuronal cells undergo death, lead to reduced NeuN expression after 
ischemia. An interesting observation was that HIF-α, whose expression increases in 
post-ischemic inflammation, was significantly reduced after ischemia in MOAP-1-/- 









CHAPTER 5 EFFECTS OF MOAP-1 DEFICIENCY IN THE 
EXPERIMENTAL TMCAO MODEL 
5.1 Introduction 
In some human strokes, thrombolysis gradually occurs with time. Therefore, 
compared with permanent MCAO, transient MCAO is a more suitable model for 
strokes with recanalization . However, although the restoration of blood restores some 
brain functions, it also produces secondary reperfusion injuries in the cortical 
penumbra, contributing to progression of infarct size at the delayed phase (Carmichael, 
2005). It has been established that the temporal evolution of infarction, the pattern of 
neutrophil infiltration and inflammatory processes differ between tMCAO and 
pMCAO. Therefore, tMCAO is a suitable tool for the study of delayed injuries and 
inflammation in the ischemic cascade and it serves as the best model for the test of 
neuroprotective therapies (Zhang et al., 1994).  
In tMCAO, the most common durations of occlusion are 60, 90 and 120 min 
(Carmichael, 2005). In this study, a 120 min occlusion time was chosen for higher 










5.2.1 MOAP-1 deficiency does not decrease susceptibility to brain damage 
after transient focal ischemia  
After 2 h of cerebral artery occlusion and 22 h of reperfusion, MOAP-1+/+ and 
MOAP-1-/- mice were euthanized and TTC staining was performed on their brain 
slices. Fig 5.1(A) shows representative stating results for these two groups of mice 
and Fig 5.1(B) shows quantification of infarct volumes. Infarct volumes did not 
demonstrate a significant difference between the two groups, indicating MOAP-1 
deficiency did not bring a neuroprotective effect to animals after transient cerebral 























Fig 5.1 Effect of MOAP-1 deletion on infarct volume after 2 hr of tMCAO. 
The effect is evaluated by TTC staining. (A) Representative TTC-stained sections 
of brain. Infarcted tissues appeared white in color as they are not stained by TTC. 
(B) Quantification of infarct volume in the brain sections. Data are mean ± SEM 





5.2.2 Effects of MOAP-1 deficiency and transient focal ischemia on expressions 
of various molecules of the ischemic cascade in the cortex 
Fig. 5.2 shows expression levels of MOAP-1 and Bax proteins in the cortex of four 
groups of animals: MOAP-1+/+ sham, MOAP-1+/+ tMCAO, MOAP-1-/- sham, and 
MOAP-1-/- tMCAO. After ischemia, MOAP-1 protein was significantly upregulated 
in MOAP-1+/+ mice. However, ischemia and MOAP-1 deletion did not affect 
expression of Bax in the cortex. 
In both MOAP-1+/+ and MOAP-1-/- mice, transient focal ischemia did not brought 
about apparent difference in expression of NeuN. Besides, compared with 
MOAP-1+/+ sham, MOAP-1 deletion did not affect NeuN expression in MOAP-1-/- 
sham. Collectively, neither transient focal ischemia nor MOAP-1 deficit affected 
expression of NeuN in the cortex (Fig. 5.3). Similar results were observed for GFAP 


































































Fig. 5.2 Expression of MOAP-1 and Bax proteins in the cortex before and after 
tMCAO in MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and subjected 
to western blot analysis using the anti-MOAP-1 and anti-Bax antibodies. Data are 































Fig. 5.3 Expression of NeuN protein in the cortex before and after tMCAO in 
MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and subjected to western 












































Fig. 5.4 Expression of GFAP protein in the cortex before and after tMCAO in 
MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and subjected to western 














Similar to what was observed after pMCAO, infarct size in MOAP-1-/- animals was 
not significantly different from that in MOAP-1+/+ animals after 2 h of focal 
ischemia followed by 22 h of reperfusion. Apparent differences in Bax, NeuN and 
GFAP expressions in the cortex were not induced by MOAP-1 deficiency or transient 
focal cerebral ischemia. This observation was different from those seen in chapter 4. 
A possible reason would be that ischemic injuries after tMCAO were less severe than 
those in pMCAO and reperfusion injuries complicated ischemic processes after 
tMCAO such that MOAP-1’s effects were masked.  
  A result was that MOAP-1 expression was significantly increased in the cortex 
after tMCAO in MOAP-1+/+ mice compared to sham-operated animals. In various 
mammalian cell lines, it was reported that MOAP-1 degradation was inhibited and 
MOAP-1 level was greatly increased upon death stimuli (Tan et al., 2001). Therefore, 
our result is consistent with in vitro findings in this aspect. Since MOAP-1 was 
proven to be proapoptotic in these cell lines, one might expect to see a decrease in 
infarction volume in MOAP-1-/- mice than in MOAP-1+/+ mice after tMCAO. 
However, this difference was not observed. A possible explanation would be that 
MOAP-1 may exert some other functions that counteract its proapoptotic effects after 







CHAPTER 6 EFFECTS OF MOAP-1 DEFICIENCY IN THE 
EXPERIMENTAL TBCCAO MODEL 
6.1 Introduction 
In recent years, increasing attention has been paid to global cerebral ischemia models 
(Ginsberg and Busto, 1989). The two-vessel occlusion model is a less invasive 
technique compared with the traditionally known four-vessel occlusion model. At the 
moment that the two CCAs are occluded, cerebral blood flow reduced to less than 
10% abruptly. In comparison with focal ischemia models, which normally produce 
localized injuries, global ischemia models affect more widespread brain regions 
(Ginsberg and Busto, 1989). Twenty four hours after tBCCAO, infarct volumes are 
far less pronounced than those observed in MCAO models; however, substantial 
neuronal alterations are induced in selectively vulnerable brain regions although 
occlusion only lasts for 30 min (Ginsberg and Busto, 1989). Besides, the usage of a 
suture in MCAO associates with a risk for subarachnoid hemorrhage, whereas this 
risk is not present in BCCAO (Schmid-Elsaesser et al., 1998). Therefore, this model 
demonstrates different underlying ischemic processes and patterns to MCAO models. 









6.2.1 Effects of MOAP-1 deficiency and transient global ischemia on 
expressions of various molecules of the ischemic cascade in the cerebellum 
After 30 min of global ischemia, expression of MOAP-1 was not significantly 
changed in MOAP-1+/+ mice, demonstrating transient global ischemia did not induce 

































Fig. 6.1 Expression of MOAP-1 protein in the cerebellum before and after 
tBCCAO in MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and 
subjected to western blot analysis using the anti-MOAP antibody. Data are presented 
as mean ± SEM, N = 3. 
 
In both MOAP-1+/+ and MOAP-1-/- mice, 30 min of global ischemia did not bring 
about apparent difference in expressions of NeuN and Bax. Besides, compared with 




MOAP-1-/- sham. Collectively, neither transient global ischemia nor MOAP-1 deficit 




























































Fig. 6.2 Expression of NeuN and Bax proteins in the cerebellum before and after 
tBCCAO in MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and 
subjected to western blot analysis using the anti-NeuN and anti-Bax antibodies. Data 




6.2.2 Effects of MOAP-1 deficiency and transient global ischemia on 
expressions of various molecules of the ischemic cascade in the hippocampus 
After 30 min of global ischemia, no apparent difference occurred for MOAP-1 
expression in MOAP-1+/+ mice in the hippocampus. Regarding the expression of Bax, 
transient global ischemia did not brought about apparent difference in expression of 
Bax in MOAP-1+/+ and MOAP-1-/- mice. Besides, compared with MOAP-1+/+ 
sham, MOAP-1 deletion did not affect Bax expression in MOAP-1-/- sham. 
Collectively, neither transient global ischemia nor MOAP-1 deficit affected 
expression of Bax in the hippocampus (Fig. 6.3). Similar results were observed for 











































































Fig. 6.3 Expression of MOAP-1 and Bax proteins in the hippocampus before and 
after tBCCAO in MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and 
subjected to western blot analysis using the anti-MOAP-1 and anti-Bax antibodies. 





































Fig. 6.4 Expression of NeuN protein in the hippocampus before and after 
tBCCAO in MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and 
subjected to western blot analysis using the anti-NeuN antibody. Data are presented as 










































Fig. 6.5 Expression of MMP9 protein in the hippocampus before and after 
tBCCAO in MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and 
subjected to western blot analysis using the anti-MMP9 antibody. Data are presented 
as mean ± SEM, N = 3. 
 
6.2.3 Effects of MOAP-1 deficiency and transient global ischemia on 
expressions of various molecules of the ischemic cascade in the striatum 
After 30 min of global ischemia, no apparent difference occurred for MOAP-1 and 
Bax expressions in MOAP-1+/+ mice in the striatum. In MOAP-1-/- mice, no 
significant changes of Bax levels were observed after ischemia as well. Besides, 
compared with MOAP-1+/+ animals, MOAP-1 deletion did not affect Bax expression 
in both sham and animals that underwent global ischemia. Collectively, neither 
transient global ischemia nor MOAP-1 deficit affected expression of Bax in the 
striatum (Fig. 6.6). Similar results were observed for expressions of NeuN (Fig. 6.7) 


































































Fig. 6.6 Expression of MOAP-1 and Bax proteins in the striatum before and after 
tBCCAO in MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and 
subjected to western blot analysis using the anti-MOAP-1 and anti-Bax antibodies. 





































Fig. 6.7 Expression of NeuN protein in the striatum before and after tBCCAO in 
MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and subjected to western 















































Fig. 6.8 Expression of MMP9 protein in the striatum before and after tBCCAO 
in MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and subjected to 
western blot analysis using the anti-MMP9 antibody. Data are presented as mean ± 
SEM, N = 3. 
 
6.2.4 Effects of MOAP-1 deficiency and transient global ischemia on 
expressions of various molecules of the ischemic cascade in the cortex 
After 30 min of global ischemia, no apparent difference occurred for MOAP-1 
expression in MOAP-1+/+ mice in the cortex (Fig. 6.9). Regarding the expressions of 
NeuN and Bax, transient global ischemia did not brought about significant changes in 
expressions of NeuN and Bax in MOAP-1+/+ and MOAP-1-/- mice. Besides, 
compared with MOAP-1+/+ sham, MOAP-1 deletion did not affect NeuN and Bax 
expression in both sham and animals that underwent global ischemia. Collectively, 
neither transient global ischemia nor MOAP-1 deficit affected expression of NeuN 




HIF-α (Fig. 6.11). However, in MOAP-1-/- animals, 30 min of global ischemia led to 
































Fig. 6.9 Expression of MOAP-1 protein in the cortex before and after tBCCAO 
in MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and subjected to 
western blot analysis using the anti-MOAP-1 antibody. Data are presented as mean ± 





































































Fig. 6.10 Expression of NeuN and Bax proteins in the cortex before and after 
tBCCAO in MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and 
subjected to western blot analysis using the anti-NeuN and anti-Bax antibodies. Data 

































    
 
Fig. 6.11 Expression of HIF-α and MMP9 proteins in the cortex before and after 
tBCCAO in MOAP-1 +/+ and MOAP-/- mice. Proteins were extracted and 
subjected to western blot analysis using the anti-HIF-α and anti-MMP9 antibodies. 





Since global ischemia affects more widespread brain structures, more brain regions 
were studied in this section. However, no statistically significant differences were 
obtained from analysis of the cerebellum, hippocampus, striatum and cortex,   
except that the level of MMP9 was significantly increased in the cortex of MOAP-1-/- 
mice after tBCCAO, as shown in Fig. 6.11. This observation indicates that MOAP-1 
may interfere with effects of metalloproteinases in the cortex such that its deletion 
leads to increased expression of MMP9. In spite of the detrimental effects that MMP9 
exerts in the progression of cerebral injuries, MMP9 is also reported to bring 
beneficial effects after injury. It contributes to termination of inflammation in the 
CNS by promoting the degradation of various chemokines, such as IL-1β (Campbell 
and Pagenstecher, 1999; Yong et al., 2001). Therefore, the significant augmentation 
of MMP9 in MOAP-1-/- mice after tBCCAO could simultaneously produce both 
detrimental and beneficial processes. Further investigation is needed for a better 












CHAPTER 7 CONCLUSIONS 
Collectively, our study has shown that MOAP-1 protein is ubiquitously expressed in 
the mouse brain. Moreover, it is expressed in astrocytes and other glial cells. 
Furthermore, MOAP-1 deletion does not affect basal levels of Bax in the brain. In 
addition, MOAP-1 deficiency does not appear to increase ischemic damages in the 
mouse stroke models.  
  The major limitation of this work is that data from only 3 animals per experimental 
group was studied and discussed in all western blot analysis. More meaningful results 
could be obtained if data from more animals were included in each experimental 
group. Besides, various markers that are pathophysiologically more relevant in 
neurons were studied in this study when it was found that MOAP-1 is only expressed 
in non-neuronal brain cells. Further investigations on astrocyte/microglial markers are 
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